GlassScriptPhysician profile
Jerry Lamont Mckenzie
NPI 1053679407
$1,252.32
in general payments reported to CMS, 2019-2025
22 companies · $416 in 2025
The $416 reported for 2025 was more than what 78% of Geriatric Medicine (Family Medicine) providers received nationally (typical 2025 total: $119).
See the full distribution for Geriatric Medicine (Family Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $391 · 2020: $28.78 · 2022: $31.69 · 2023: $243 · 2024: $142 · 2025: $416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $801.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $800.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $221.83 | 2019-2025 | Breztri, Farxiga |
| Novo Nordisk INC | $175.29 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Amarin Pharma, INC. | $124.21 | 2019 | |
| Pfizer INC. | $123.68 | 2019-2023 | |
| Amgen INC. | $80.91 | 2020-2025 | Krystexxa, Repatha, Otezla |
| Abbvie INC. | $69.37 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $68.68 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $52.62 | 2023-2024 | Gemtesa, Aptiom |
| Soleno Therapeutics, INC. | $52.44 | 2025 | Vykat Xr |
| Lilly USA, LLC | $45.02 | 2024-2025 | Mounjaro, Zepbound, Kisunla |
| Exact Sciences Corporation | $38.26 | 2025 | Cologuard Collection Kit |
| Dexcom, INC. | $24.78 | 2023 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $24.10 | 2025 | |
| Phadia US INC. | $23.11 | 2025 | Immunocap |
| Insulet Corporation | $23.02 | 2024 | Omnipod |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $18.48 | 2025 | Xhance, Nuzyra |
| Abbott Laboratories | $17.74 | 2024 | Proclaim |
| Corcept Therapeutics | $16.50 | 2025 | Korlym |
| Astellas Pharma US INC | $14.71 | 2025 | Veozah |
| Merck Sharp & Dohme LLC | $14.47 | 2019 | |
| Mylan Specialty L.P. | $12.44 | 2019 | |
| Sonex Health, INC. | $10.66 | 2025 | Sx-One Microknife |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerry Mckenzie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.